Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Naidu Chekuru

Pulmonary Disease Lubbock, TX Medical Doctor

NPI 1073515433 CMS profile 275172

3621 22Nd St, Ste 400, Lubbock, TX 79410

Open in the dashboard

General payments

$6,066

350 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Naidu Chekuru of Lubbock, TX is reported in the CMS Open Payments database as having received $6,066 across 350 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $59 3
2024 General $122 5
2023 General $819 44
2022 General $1,425 75
2021 General $1,631 96
2020 General $940 59
2019 General $1,071 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Naidu Chekuru
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Naidu Chekuru were reported at $59. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Naidu Chekuru Pulmonary Disease median Middle half National median
2019 $1,071 $377 $109–$1,340 $163
2020 $940 $230 $56–$907 $114
2021 $1,631 $269 $68–$1,072 $132
2022 $1,425 $390 $100–$1,457 $149
2023 $819 $419 $114–$1,659 $160
2024 $122 $476 $123–$1,818 $164
2025 $59 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,899 120 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,031 62 payments
  3. Grifols USA, LLC $472 25 payments
  4. AstraZeneca Pharmaceuticals LP $366 22 payments
  5. Actelion Pharmaceuticals US, Inc. $291 18 payments
  6. Janssen Pharmaceuticals, Inc $283 14 payments
  7. Sunovion Pharmaceuticals Inc. $246 11 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $233 10 payments
  9. Pfizer Inc. $196 10 payments
  10. Regeneron Healthcare Solutions, Inc. $152 8 payments
  11. Other $896 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,053 349 payments
  2. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,321 81 payments
  2. OFEV $1,040 63 payments
  3. ANORO ELLIPTA $508 33 payments
  4. Prolastin-C Liquid $472 25 payments
  5. SPIRIVA RESPIMAT $338 20 payments
  6. UPTRAVI $291 18 payments
  7. XARELTO $283 14 payments
  8. NUCALA $276 16 payments
  9. OPSUMIT $256 16 payments
  10. LONHALA MAGNAIR $246 11 payments
  11. Other $3,201 171 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

350 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record